Core Points - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific deadlines for filing lead plaintiff motions [1] Company Summaries Molina Healthcare, Inc. (NYSE: MOH) - Class Period: February 5, 2025 – July 23, 2025 - Allegations include false and misleading statements regarding medical cost trend assumptions, dislocation between premium rates and medical costs, and reliance on reduced utilization of services, leading to likely cuts in financial guidance for fiscal year 2025 [2] Marex Group plc (NASDAQ: MRX) - Class Period: May 16, 2024 – August 5, 2025 - Allegations include selling over-the-counter financial instruments to itself, inconsistencies in financial statements, and reliance issues with financial statements, resulting in misleading positive statements about the company's operations and prospects [3] WPP plc (NYSE: WPP) - Class Period: February 27, 2025 – July 8, 2025 - Allegations include the media arm's inability to handle macroeconomic challenges and loss of market share, leading to misleading positive statements about the company's business and operations [4]

Core Viewpoint - A class action lawsuit has been filed against Marex Group plc due to allegations of financial improprieties, including a multi-year accounting scheme that concealed losses and inflated profits [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Marex shares from May 16, 2024, to August 5, 2025 [1][2]. - Investors have until December 8, 2025, to seek appointment as lead plaintiff [2]. Group 2: Allegations Against Marex - NINGI Research reported that Marex engaged in a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions [3]. - The report highlighted discrepancies in intercompany receivables and loans across over 56 entities, amounting to multi-million-dollar differences [3]. - Marex allegedly concealed nearly $1 billion in off-balance-sheet derivatives, inflating operating cash flow by misclassifying structured note issuance as income [4]. Group 3: Market Reaction - Following the release of the report, Marex's stock price fell by $2.33, or 6.2%, closing at $35.31, resulting in significant investor losses [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Marex Group plc who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 8, 2025 deadline for lead plaintiff applications [1]. Group 1: Legal Action Details - Investors who purchased Marex securities between May 16, 2024, and August 5, 2025, may be eligible for compensation without upfront costs through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - The lawsuit alleges that Marex made materially false statements and failed to disclose critical information regarding its financial practices, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Points - Rosen Law Firm is reminding investors who purchased securities of Marex Group plc between May 16, 2024, and August 5, 2025, about the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Case Details - The lawsuit alleges that during the Class Period, Marex made materially false and misleading statements and failed to disclose critical information, including: 1. Marex sold over-the-counter financial instruments to itself 2. There were inconsistencies in financial statements between subsidiaries and related parties 3. Marex's financial statements could not be relied upon 4. Positive statements about Marex's business were materially misleading [4] Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions, as many firms may not have the necessary experience or resources [3] - Rosen Law Firm has achieved significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by December 8, 2025 [3][6]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [6]. - A report from NINGI Research accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions, including a fabricated receivable of $17 million and nearly $1 billion in concealed derivatives exposure [7]. - Following the release of the report, Marex's stock experienced a significant decline of 6.2%, closing at $35.31 on heavy trading volume [9]. Group 2: Legal Actions and Investor Options - Investors who purchased Marex securities between May 16, 2024, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995, indicating its capability in handling such cases [5]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with no impact on their ability to share in any recovery [10].

Core Points - Rosen Law Firm is encouraging investors of Marex Group plc who incurred losses exceeding $100,000 during the Class Period from May 16, 2024, to August 5, 2025, to secure legal counsel before the December 8, 2025, deadline for lead plaintiff applications [1][5]. Group 1: Legal Action Details - Investors who purchased Marex securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - The lawsuit alleges that Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in securing significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 [4].

Core Points - Rosen Law Firm is reminding investors who purchased Marex Group plc securities between May 16, 2024, and August 5, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Marex securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by December 8, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements [5]. - It is claimed that Marex's financial statements could not be relied upon, and positive statements about the company's business were materially misleading [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit set for December 8, 2025 [3][8]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements, failing to disclose significant issues such as selling over-the-counter financial instruments to itself and inconsistencies in financial statements [6]. - A report by NINGI Research accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions, including a fabricated receivable of $17 million and nearly $1 billion in concealed derivatives exposure [7]. - Following the release of the report, Marex's stock experienced a significant decline of 6.2%, closing at $35.31 [9]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased Marex securities between May 16, 2024, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [2]. - The role of lead plaintiff in the class action lawsuit is designated for the investor with the largest financial interest, who will oversee the litigation on behalf of the class [10]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Marex's conduct [11].

Core Viewpoint - Rosen Law Firm is encouraging investors of Marex Group plc who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 8, 2025 deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - The class period for the Marex Group plc securities class action is from May 16, 2024, to August 5, 2025 [1]. - Investors who purchased Marex securities during this period may be eligible for compensation without any upfront costs through a contingency fee arrangement [2]. - To participate in the class action, investors must apply by December 8, 2025, to serve as lead plaintiff, representing other class members [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements secured for investors [4]. Group 3: Allegations Against Marex - The lawsuit alleges that during the class period, Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements [5]. - As a result of these actions, Marex's financial statements were deemed unreliable, leading to misleading positive statements about the company's business and operations [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status by December 8, 2025 [1][3]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false or misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [3]. - Specific allegations include a multi-year accounting scheme involving off-balance-sheet entities, fictitious transactions, and misleading disclosures to hide losses and inflate profits, with examples such as a $17 million fabricated receivable and nearly $1 billion in concealed derivatives exposure [4]. - Following the release of a damaging report, Marex's stock experienced a significant decline of 6.2%, closing at $35.31 on heavy trading volume [5]. Group 2: Legal Proceedings and Investor Actions - The lead plaintiff in the class action will be the investor with the largest financial interest who is adequate and typical of class members, and any member of the class may move to serve as lead plaintiff [6]. - Faruqi & Faruqi encourages individuals with information regarding Marex's conduct, including whistleblowers and former employees, to come forward [6].